Free Trial

Geoffrey Porges Analyst Performance

Analyst at Leerink Partners

Geoffrey Porges is a stock analyst at Leerink Partners in the medical sector, covering 3 publicly traded companies. Over the past year, Geoffrey Porges has issued 1 stock ratings, including and buy recommendations. While full access to Geoffrey Porges' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Geoffrey Porges' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 4 Years
Buy Recommendations
100.00% 5 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%5 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
2 companies
NYSE
33.3% of companies on NYSE
1 company

Geoffrey Porges, an analyst at Leerink Partners, currently covers 3 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Geoffrey Porges of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
MED - DRUGS
1 company
33.3%

Geoffrey Porges' Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
3/2/2026Boost Price Target$24.29$49.00Outperform